Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model

Journal of Viral Hepatitis

Volumn 9, Issue 2, 2002, Pages 114-122

  Deuffic Burban, Sylvie ^a,c   Poynard, T ^b   Valleron, A J ^a,c  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Chronic hepatitis C; Fibrosis; Markov modelling; Prediction; Risk factors; Treatment

Indexed keywords

INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INFANT; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; TREATMENT OUTCOME;

EID: 0036902302     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00340.x     Document Type: Article

References (13)

1. Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of alpha interferon treatment on liver fibrosis progression in chronic hepatitis C. a dynamic view. Gastroenterology 1999; 116: 378-386.
2. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
3. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
4. Longini IM, Clark WS, Gardner LI, Brundage JF. The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: A Markov modeling approach. J Acq Immun Def Synd 1991; 4: 1141-1147.
5. Rouzioux C, Costagliola D, Burgard M et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. Am J Epidemiol 1995; 142: 1330-1337.
6. Chouquet C, Richardson S, Burgard M et al. Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: Bayesian estimation using a mixture. Stat Med 1999; 18: 815-833.
7. Marshall G, Jones RH. Multi-state models and diabetic retinopathy. Stat Med 1995; 14: 1975-83.
8. Deuffic S, Buffat L, Poynard T, Valleron A-J. Modeling the HCV epidemic in France. Hepatology 1999; 29: 1596-1601.
9. Deuffic S, Poynard T, Valleron A-J. Correlation between HCV prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepatitis 1999; 6: 411-413.
10. Yazdanpanah Y, Boëlle P-Y, Carrat F, Guiguet M, Abiteboul D, Valleron A-J. Risk of hepatitis C virus transmission to surgeons and nurses from infected patients: Model-based estimates in France. J Hepatol 1999; 30: 765-769.
11. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C. Morphometric analysis of repeated biopsies. Hepatology 1997; 25: 1028-1031.
12. Pol S, Fontaine H, Carnot F et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C. A comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 12-19.
13. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical Recipes in C. Cambridge: Cambridge University Press, 1988.